The biology and management of non-small cell lung cancer
RS Herbst, D Morgensztern, C Boshoff - Nature, 2018 - nature.com
Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been
achieved over the past two decades, increasing our understanding of the disease biology …
achieved over the past two decades, increasing our understanding of the disease biology …
Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted …
Recent large scale genomic studies from the Clinical Lung Cancer Genome Project have
identified different driver gene mutations in the subtypes of non-small cell lung carcinoma …
identified different driver gene mutations in the subtypes of non-small cell lung carcinoma …
Radiotherapy induces responses of lung cancer to CTLA-4 blockade
SC Formenti, NP Rudqvist, E Golden, B Cooper… - Nature medicine, 2018 - nature.com
Focal radiation therapy enhances systemic responses to anti-CTLA-4 antibodies in
preclinical studies and in some patients with melanoma,–, but its efficacy in inducing …
preclinical studies and in some patients with melanoma,–, but its efficacy in inducing …
Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing
Cancer immunotherapies have shown sustained clinical responses in treating non-small-
cell lung cancer,–, but efficacy varies and depends in part on the amount and properties of …
cell lung cancer,–, but efficacy varies and depends in part on the amount and properties of …
[HTML][HTML] Oncogenic signaling pathways in the cancer genome atlas
Genetic alterations in signaling pathways that control cell-cycle progression, apoptosis, and
cell growth are common hallmarks of cancer, but the extent, mechanisms, and co …
cell growth are common hallmarks of cancer, but the extent, mechanisms, and co …
[HTML][HTML] Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer
KA Hoadley, C Yau, T Hinoue, DM Wolf, AJ Lazar… - Cell, 2018 - cell.com
We conducted comprehensive integrative molecular analyses of the complete set of tumors
in The Cancer Genome Atlas (TCGA), consisting of approximately 10,000 specimens and …
in The Cancer Genome Atlas (TCGA), consisting of approximately 10,000 specimens and …
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
F Skoulidis, ME Goldberg, DM Greenawalt… - Cancer discovery, 2018 - AACR
KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously
reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS …
reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS …
Genetic and transcriptional evolution alters cancer cell line drug response
Human cancer cell lines are the workhorse of cancer research. Although cell lines are
known to evolve in culture, the extent of the resultant genetic and transcriptional …
known to evolve in culture, the extent of the resultant genetic and transcriptional …
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
Visual inspection of histopathology slides is one of the main methods used by pathologists
to assess the stage, type and subtype of lung tumors. Adenocarcinoma (LUAD) and …
to assess the stage, type and subtype of lung tumors. Adenocarcinoma (LUAD) and …
The UCSC Xena platform for public and private cancer genomics data visualization and interpretation
M Goldman, B Craft, M Hastie, K Repečka, F McDade… - biorxiv, 2018 - biorxiv.org
UCSC Xena is a visual exploration resource for both public and private omics data,
supported through the web-based Xena Browser and multiple turn-key Xena Hubs. This …
supported through the web-based Xena Browser and multiple turn-key Xena Hubs. This …